Introduction: Denosumab, a fully human anti-RANKL monoclonal antibody, reduces the
incidence of skeletal-related events in patients with bone metastases from solid tumors. We …

… Moreover, a recently published subgroup analysis of a randomized trial reported similar
results with the present study [18]. In addition, several pooled analysis or meta-analysis has …

… Subgroup analyses of randomized … analysis was conducted with the aim of describing
the prevalence and methodological characteristics of the subgroup analyses in randomized …

… -specific subgroup analysis of the efficacy and safety of eribulin compared with dacarbazine
in patients with LPS, an independently randomized stratified subgroup of this phase III trial. …

… elderly patients further, we conducted preplanned subgroup analyses of patients age < 65
and ≥ 65 years enrolled in the multinational, randomized Phase III study TAX 326. This study …

… The objective of this subgroup analysis was to further evaluate the potential clinical benefit
of nivolumab in patients with mRCC treated beyond investigator-assessed first progression. …

… To assess the efficacy of EP in these patients, pre-specified subgroup analyses of efficacy
and safety were conducted and are reported herein. In addition, we report a post hoc analysis …

… Stratification factors were not included in any of the models for the subgroup analyses. …
Due to the small sample sizes, comparisons for subgroup analysis are presented between …

… soft-tissue sarcoma, we performed a subgroup analysis of the earlier described EORTC 62961
trial … (R0, R1) were selected for the present analysis. Resection status was reviewed by an …

… A subgroup analysis was conducted in Japanese patients enrolled in the randomized Phase
III trial of axitinib versus sorafenib after failure of one prior systemic therapy for metastatic …